- Getting Pregnant Buntis Ba Ako Kung Isang Linggo Nang Delayed Ang Period Ko?
- Preschooler Your Child Needs a Strict Parent. Here's How to Be a Good One
- Fitness & Nutrition 20 Lbs Ang Nabawas Sa Timbang Ni Mommy Dahil Sa Jumping Rope
- News Infants In Baby Switching Case Returned To Rightful Parents; Rizal Hospital Offers Refund
Bayer Launches First Oral Contraceptive to Treat Heavy Menstrual Bleeding (HMB)Many women suffer from heavy menstrual bleeding (HMB) and do not know it.
Bayer HealthCare Pharmaceuticals recently launched an oral contraceptive estradiol valerate/dienogest (Qlaira®) which significantly reduces heavy menstrual bleeding (HMB).
Estradiol valerate/dienogest (Qlaira®), a combined oral contraceptive, has been approved for the treatment of HMB in women without organic pathology who desire an oral contraceptive as their method of birth control.
Estradiol valerate/dienogest (Qlaira®) is the first oral contraceptive to treat HMB, providing women with a non-invasive, short-acting treatment that preserves their reproductive health. It is also the first in a new class of oral contraceptives to deliver estradiol, the same estrogen produced by a woman’s body.
Clinical trials show that Estradiol valerate/dienogest (Qlaira®) reduces menstrual bleeding by 88 percent after six months of treatment versus baseline. Reduction in HMB is a class effect; however oral contraceptives are typically known to reduce menstrual bleeding by 35-43%.
It is estimated that up to 52 percent of women experience HMB at some point in their lives. In clinical practices, the prevalence of HMB is likely to be underestimated as only a minority of women seek medical advice for this condition.ADVERTISEMENT - CONTINUE READING BELOW1 of 2 NEXT
CONTINUE READING BELOWRecommended Videos
Trending in Summit Network